과제정보
This work was supported by the Korea National Enterprise for Clinical Trials grant funded by the Korean government (Ministry of Health and Welfare) (No.HE21C0006).
참고문헌
- Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, et al. Radiological Society of North America expert consensus statement on reporting chest CT findings related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA - Secondary publication. J Thorac Imaging 2020;35:219-227
- Caruso D, Guido G, Zerunian M, Polidori T, Lucertini E, Pucciarelli F, et al. Post-acute sequelae of COVID-19 pneumonia: six-month chest CT follow-up. Radiology 2021;301:E396-E405
- Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology 2021;299:E177-E186
- Pan F, Yang L, Liang B, Ye T, Li L, Li L, et al. Chest CT patterns from diagnosis to 1 year of follow-up in patients with COVID-19. Radiology 2022;302:709-719
- Besutti G, Monelli F, Schiro S, Milone F, Ottone M, Spaggiari L, et al. Follow-up CT patterns of residual lung abnormalities in severe COVID-19 pneumonia survivors: a multicenter retrospective study. Tomography 2022;8:1184-1195
- Bocchino M, Lieto R, Romano F, Sica G, Bocchini G, Muto E, et al. Chest CT-based assessment of 1-year outcomes after moderate COVID-19 pneumonia. Radiology 2022:305;479-485
- Luger AK, Sonnweber T, Gruber L, Schwabl C, Cima K, Tymoszuk P, et al. Chest CT of lung injury 1 year after COVID-19 pneumonia: the CovILD study. Radiology 2022;304:462-470
- Thornton CS, Huntley K, Berenger BM, Bristow M, Evans DH, Fonseca K, et al. Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values. Antimicrob Resist Infect Control 2022;11:28
- Santana ANC, Melo FX, Xavier FD, Amado VM. Migratory pulmonary infiltrates in a patient with COVID-19 and lymphoma. J Bras Pneumol 2021;47:e20200528
- John TM, Malek AE, Mulanovich VE, Adachi JA, Raad II, Hamilton AR, et al. Migratory pulmonary infiltrates in a patient with COVID-19 infection and the role of corticosteroids. Mayo Clin Proc 2020;95:2038-2040
- Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health.com Web stie. https://www.covid19treatmentguidelines.nih.gov. Published September 26, 2022. Acceseed September 30, 2022
- Andersen KM, Bates BA, Rashidi ES, Olex AL, Mannon RB, Patel RC, et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatol 2022;4:e33-e41
- Bonuomo V, Ferrarini I, Dell'Eva M, Sbisa E, Krampera M, Visco C. COVID-19 (SARS-CoV-2 infection) in lymphoma patients: a review. World J Virol 2021;10:312-325
- Yasuda H, Mori Y, Chiba A, Bai J, Murayama G, Matsushita Y, et al. Resolution of one-year persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab maintenance therapy: a follow-up report and literature review of cases with prolonged infections. Clin Lymphoma Myeloma Leuk 2021;21:e810-e816
- Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005;5:251-262
- Strangfeld A, Schafer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 2021;80:930-942
- Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis 2021;80:1355-1356
- Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. Ann Intern Med 2021;174:1572-1585
- Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 2021;3:e419-e426
- Kos I, Balensiefer B, Roth S, Ahlgrimm M, Sester M, Schmidt T, et al. Prolonged course of COVID-19-associated pneumonia in a B-cell depleted patient after rituximab. Front Oncol 2020;10:1578
- Bitoun S, Henry J, Desjardins D, Vauloup-Fellous C, Dib N, Belkhir R, et al. Rituximab impairs B cell response but not T cell response to COVID-19 vaccine in autoimmune diseases. Arthritis Rheumatol 2022;74:927-933
- Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol 2022;4:e177-e187
- Desai SR, Lynch DA, Elicker BM, Devaraj A, Sverzellati N. Other idiopathic interstitial pneumonias: cryptogenic organizing pneumonia, acute interstitial pneumonia, smoking-related interstitial lung diseases, lymphoid interstitial pneumonia. In: Desai S, Lynch D, Elicker BM, Devaraj A, Sverzellati N, eds. Webb, Muller and Naidich's high-resolution CT of the lung, 6th ed. Philadelphia: Wolters Kluwer Health, 2021:234-243
- Baque-Juston M, Pellegrin A, Leroy S, Marquette CH, Padovani B. Organizing pneumonia: what is it? A conceptual approach and pictorial review. Diagn Interv Imaging 2014;95:771-777
- Nakajima Y, Ogai A, Furukawa K, Arai R, Anan R, Nakano Y, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother 2021;27:387-389
- Otsuka Y, Kobayashi T. Case report: a patient with COVID-19 under myelosuppression induced by chemotherapy. Am J Trop Med Hyg 2020;103:1983-1985
- Fujii H, Tsuji T, Sugitani M, Matsumoto Y, Yuba T, Tanaka S, et al. Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: a case report. Curr Probl Cancer 2021;45:100739